PMID- 36172377
OWN - NLM
STAT- MEDLINE
DCOM- 20220930
LR  - 20221003
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Effectiveness and safety of Belimumab combined with standard therapy in severe 
      active lupus nephritis requiring kidney replacement therapy: A case report and 
      literature review.
PG  - 977377
LID - 10.3389/fimmu.2022.977377 [doi]
LID - 977377
AB  - Lupus Nephritis (LN) is the most common manifestation of severe organ damage for 
      systemic lupus erythematosus (SLE) patients. Severe active LN could result in 
      acute kidney injury (AKI), which could even require Kidney Replacement Therapy 
      (KRT). Therefore, there needs to be a more proactive and safe induction therapy 
      to quickly and effectively control renal immune inflammation, maintain kidney 
      function or reverse kidney damage. While multiple clinical studies have proven 
      the efficacy and safety of Belimumab in treating SLE and LN, these studies have 
      not included cases of severe LN requiring KRT. We observed the effectiveness and 
      safety of Belimumab in treating four severe active LN patients undergoing KRT. 
      With Belimumab administered at a dosage of 10mg/kg, all four patients were able 
      to discontinue KRT with no adverse events (AEs) to date ultimately. These cases 
      provided an excellent basis for the application of Belimumab combined with 
      standard therapy to LN patients with a medium to severe kidney injury.
CI  - Copyright (c) 2022 Zhang, Zeng, Ge, Liu, Xing and Mao.
FAU - Zhang, Chengning
AU  - Zhang C
AD  - Department of Nephrology, The First Affiliated Hospital of Nanjing Medical 
      University (Jiangsu Province Hospital), Nanjing, China.
FAU - Zeng, Ming
AU  - Zeng M
AD  - Department of Nephrology, The First Affiliated Hospital of Nanjing Medical 
      University (Jiangsu Province Hospital), Nanjing, China.
FAU - Ge, Yifei
AU  - Ge Y
AD  - Department of Nephrology, The First Affiliated Hospital of Nanjing Medical 
      University (Jiangsu Province Hospital), Nanjing, China.
FAU - Liu, Kang
AU  - Liu K
AD  - Department of Nephrology, The First Affiliated Hospital of Nanjing Medical 
      University (Jiangsu Province Hospital), Nanjing, China.
FAU - Xing, Changying
AU  - Xing C
AD  - Department of Nephrology, The First Affiliated Hospital of Nanjing Medical 
      University (Jiangsu Province Hospital), Nanjing, China.
FAU - Mao, Huijuan
AU  - Mao H
AD  - Department of Nephrology, The First Affiliated Hospital of Nanjing Medical 
      University (Jiangsu Province Hospital), Nanjing, China.
LA  - eng
PT  - Case Reports
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220912
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Immunosuppressive Agents)
RN  - 73B0K5S26A (belimumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/adverse effects
MH  - Humans
MH  - Immunosuppressive Agents/adverse effects
MH  - *Lupus Erythematosus, Systemic/drug therapy
MH  - *Lupus Nephritis/chemically induced/drug therapy
PMC - PMC9511409
OTO - NOTNLM
OT  - acute kidney injury
OT  - belimumab
OT  - case report
OT  - kidney replacement therapy
OT  - severe active lupus nephritis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/09/30 06:00
MHDA- 2022/10/01 06:00
PMCR- 2022/01/01
CRDT- 2022/09/29 02:17
PHST- 2022/06/24 00:00 [received]
PHST- 2022/08/24 00:00 [accepted]
PHST- 2022/09/29 02:17 [entrez]
PHST- 2022/09/30 06:00 [pubmed]
PHST- 2022/10/01 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.977377 [doi]
PST - epublish
SO  - Front Immunol. 2022 Sep 12;13:977377. doi: 10.3389/fimmu.2022.977377. eCollection 
      2022.